pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·12h ago·1 min read
save

WuXi AppTec posts six-month revenue higher than Lonza for first time

Aug 5, 2026·read at Endpoints ↗Positive

WuXi AppTec, a Chinese contract manufacturing organization, has reported that its revenue over the most recent six-month period exceeded that of Swiss CDMO Lonza for the first time.

The increase comes despite heightened scrutiny from the U.S. Department of Defense, which has been reviewing the company's operations.

The company’s growth suggests it continues to expand its role in the global pharmaceutical manufacturing market, while Lonza’s revenue lag indicates competitive pressure.

No further financial details were disclosed in the brief report.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “In a first, WuXi AppTec surpasses Lonza’s six-month revenue”

read at Endpoints ↗
84 words · retrieved 11h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
CRO/CDMO3

related stories

  • 16h agoPfizer ramps up ongoing restructuring, Lisata axes 72% of staffBioSpace
  • Jul 28The FDA was all in on AI. Will that change?BioPharma Dive
  • Jul 28Acrosian debuts as AI-focused biometrics CROFierce Biotech
  • Jul 28As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskBioSpace
  • Jul 27From confidence to capital: Positioning biotech for the next growth cycleBioPharma Dive